tirzepatide nash phase 3 Tirzepatide: First Approval | Drugs Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis

20,21 The confirmatory secondary end point (controlled for multiple comparisons) was an improvement of at least one fibrosis stage and no worsening of NASH (with worsening defined as an increase of 1 point in either the lobular inflammation score or the hepatocyte ballooning score according to the NASH Clinical Research Network criteria) after 72 weeks

Women using GLP-1 medications frequently reported menstrual irregularities, including changes in cycle timing and flow

L-Carnitine is an amino acid that supports healthy heart and fat metabolism

I tested Limitless BPC-157 for six weeks on a minor quad strain

CCM bridges a critical gap in neuropathy diagnostics by enabling early, objective detection and longitudinal monitoring, with growing adoption in clinical and research settings worldwide